N1,N5-bis(4-bromophenyl)biguanide hydrochloride | 872090-05-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1,N5-bis(4-bromophenyl)biguanide hydrochloride
• 英文别名: 1-[amino-(4-bromoanilino)methylidene]-2-(4-bromophenyl)guanidine;hydrochloride
• CAS: 872090-05-6
• 化学式: C₁₄H₁₃Br₂N₅*ClH
• 分子量: 447.56
• InChiKey: IJKOQNDEZCTZEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.62
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.8
• 氢给体数：
  4
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-溴苯胺 、 sodium dicyanamide 在 盐酸 作用下， 以 水 为溶剂， 反应 12.0h， 以54%的产率得到N1,N5-bis(4-bromophenyl)biguanide hydrochloride
  参考文献：
  名称：

  芳基双胍实用指南 ?? 合成和结构表征

  摘要：

  通过苯胺氯化物与双氰胺或双氰胺钠的反应合成了多种 1-芳基双胍和 1,5-二芳基双胍的单盐酸盐，并通过用甲醇 NaOCH3 去质子化将双胍氯化物转化为相应的双胍。所得双胍及其盐类通过光谱方法进行了充分表征，代表性化合物的结构通过 X 射线晶体学确定。

  DOI：

  10.1139/v05-093

文献信息

• Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient
  申请人：Kim Sung Wuk

  公开号：US20120283299A1

  公开（公告）日：2012-11-08

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  提供一种具有N1-N5取代的biguanide衍生物化合物，其由Formula 1表示，或其药学上可接受的盐，以及制备该化合物的方法，以及含有该化合物作为活性成分的药物组合物。与传统药物相比，这种biguanide衍生物可能在低剂量下对AMPKα的激活和对癌细胞增殖的抑制表现出出色的效果，因此可能有助于治疗糖尿病、肥胖、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征、代谢综合征、癌症等疾病。
• BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT
  申请人：HanAll Biopharma Co., Ltd.

  公开号：EP2522653A2

  公开（公告）日：2012-11-14

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  本发明提供了一种由式 1 表示的具有 N1-N5 取代的双胍衍生物化合物或其药学上可接受的盐、其制备方法以及以其为活性成分的药物组合物。与传统药物相比，该双胍衍生物可在低剂量下表现出良好的激活 AMPKα 和抑制癌细胞增殖的效果，因此可用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征、代谢综合征、癌症等。
• Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient
  申请人：Immunomet Therapeutics Inc.

  公开号：US10376480B2

  公开（公告）日：2019-08-13

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  本发明提供了一种由式 1 表示的具有 N1-N5 取代的双胍衍生物化合物或其药学上可接受的盐、其制备方法以及以其为活性成分的药物组合物。与传统药物相比，该双胍衍生物可在低剂量下表现出良好的激活 AMPKα 和抑制癌细胞增殖的效果，因此可用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征、代谢综合征、癌症等。
• Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient
  申请人：IMMUNOMET THERAPEUTICS INC.

  公开号：US20160317478A1

  公开（公告）日：2016-11-03

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
• BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT
  申请人：Immunomet Therapeutics Inc.

  公开号：US20180256520A1

  公开（公告）日：2018-09-13

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.